Psy­che­del­ic biotech ATAI hopes to ex­pand port­fo­lio through re­search part­ner­ship with Mass Gen­er­al

5 years ago
Deals

Pfiz­er's big block­buster Xel­janz flunks its post-mar­ket­ing safe­ty study, re­new­ing harsh ques­tions for JAK class

5 years ago
R&D

Bomb squad called to As­traZeneca vac­cine plant; Lu­men nabs CARB-X award for low-cost an­tidiar­rheal

5 years ago
News Briefing

As­traZeneca CEO Pas­cal So­ri­ot sev­ers an un­usu­al board con­nec­tion, steer­ing clear of con­flicts while re­tain­ing ...

5 years ago
Bioregnum
Opinion

Leaps by Bay­er backs a pro­tein en­gi­neer­ing start­up tak­ing on Aim­mune — and Nestlé — in peanut al­ler­gy

5 years ago
Financing
Startups

Re­call re­port: Nos­trum re­calls an­oth­er lot of met­formin as car­cino­gen con­cerns con­tin­ue

5 years ago
FDA+

Fore­site re­turns to the SPAC well, as in­vestors won­der how long the run can last

5 years ago
Deals

Covid-19 roundup: EU and As­traZeneca trade blows over slow­downs; Un­usu­al unions pop up to test an­ti­bod­ies, vac­cines

5 years ago
Coronavirus

As tar­get­ed ther­a­pies get ever more pre­cise, Deer­field un­veils $50M bet on a Har­vard pro­fes­sor's chem­istry in­sights

5 years ago
Financing
Startups

Ex-MD An­der­son chief De­Pin­ho is help­ing launch an­oth­er biotech — and he's stick­ing with fa­mil­iar ground

5 years ago
Financing

As­traZeneca scores new goal on the pipeline front, adding its first AI-gen­er­at­ed tar­get to the port­fo­lio

5 years ago
R&D
AI

Agios scores its sec­ond pos­i­tive round of da­ta for its lead pipeline drug — but that won't an­swer the stub­born ...

5 years ago
R&D

Drug­mak­ers 'inch­ing ahead' in in­creas­ing ac­cess to drugs world­wide, with Glax­o­SmithK­line lead­ing the pack

5 years ago
Pharma

News brief­ing: Nestlé whips up re­search col­lab­o­ra­tion with new­ly-un­veiled Flag­ship up­start; Mar­i­anne De Backer joins ...

5 years ago
News Briefing

Vir's CMO says he's sur­prised that a low dose of their he­pati­tis B drug ap­pears promis­ing in ear­ly slice of da­ta — ...

5 years ago
R&D

My­ovant beefs up da­ta pack­age in NDA #3, boost­ing its case for longterm dos­ing of Pfiz­er-part­nered re­l­u­golix

5 years ago
R&D

Look­ing to win over some skep­ti­cal an­a­lysts, Rhythm beats the drum on in­ter­im da­ta in PhII bas­ket study for ...

5 years ago
R&D

Eli Lil­ly demon­strates that 2 an­ti­bod­ies beat 1 for guard­ing against se­vere Covid-19. But can that solve the first ...

5 years ago
Coronavirus

Covid-19 roundup: As­traZeneca, Pfiz­er come un­der fire for pro­duc­tion de­lays; Mod­er­na con­sid­ers third boost­er dose to ...

5 years ago
Coronavirus

No­var­tis' Q4 earn­ings cloud­ed by reg­u­la­to­ry set­backs on in­clisir­an, Zol­gens­ma

5 years ago
FDA+

Re­gen­eron touts pos­i­tive pre­lim­i­nary im­pact of its Covid an­ti­body cock­tail, pre­vent­ing symp­to­matic in­fec­tions in ...

5 years ago
R&D
Coronavirus

Stake­hold­ers weigh in on big da­ta at EMA fo­rum

5 years ago
FDA+

Re­vis­it­ing the 'cy­tokine stor­m' in ARDS; the painful wait for an­ti-in­flam­ma­to­ry drugs/tar­gets that solve Covid-19 ...

5 years ago
Biotech Voices

Af­ter 3 deaths rock the field, gene ther­a­py re­searchers con­tem­plate AAV's fu­ture

5 years ago
In Focus
First page Previous page 751752753754755756757 Next page Last page
A service from the Financial Times